SCHEMBL2485265

SCHEMBL2485265

C[C@@H](CN)N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
DPP4 P27487 1/20 0.41
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
KEAP1 Q14145 1/20 0.37
ALDH1A1 P00352 5/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GAA P10253 1/20 0.35
USP2 O75604 1/20 0.33
KCNA5 P22460 1/20 0.33
PKM P14618 1/20 0.31
KDM4E B2RXH2 2/20 0.31
ANPEP P15144 1/20 0.31
CYP3A4 P08684 1/20 0.30
TSHR P16473 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL39810 1.00 KMT2A (0.41) KMT2AMEN1DPP4LMNASMN1; SMN2
SCHEMBL4856749 0.82 KMT2A (0.46) KMT2AMEN1DPP4LMNASMN1; SMN2
SCHEMBL11224155 0.82 ALDH1A1 (0.37) KMT2AMEN1ALDH1A1KDM4E
SCHEMBL21096753 0.82
SCHEMBL9801362 0.79 KMT2A (0.40) KMT2AMEN1DPP4LMNASMN1; SMN2
SCHEMBL7043086 0.79 KEAP1 (0.45) KMT2AMEN1DPP4LMNASMN1; SMN2
SCHEMBL23108665 0.78 KMT2A (0.42) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL643674 0.78 KMT2A (0.42) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL21564194 0.78 KMT2A (0.42) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL11928238 0.77 DPP4 (0.39) KMT2AMEN1DPP4LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379518-A1 THIADIAZOLE-SUBSTITUTED ARYLAMIDES F. Hoffmann-La Roche AG (CH) 2011-10-26 EP disclosed
EP-2225213-A1 TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2010-09-08 EP disclosed
WO-2010069794-A1 THIADIAZOLE-SUBSTITUTED ARYLAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-06-24 WO disclosed
EP-2091927-A1 THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES F. Hoffmann-Roche AG (CH) 2009-08-26 EP disclosed
WO-2009077366-A1 TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
EP-2038264-A1 TETRAZOLE-SUBSTITUTED ARYLAMIDES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008055840-A1 THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2008-05-15 WO disclosed
WO-2008000645-A1 TETRAZOLE-SUBSTITUTED ARYLAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed